297 related articles for article (PubMed ID: 25327557)
1. A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors.
Soliman HH; Jackson E; Neuger T; Dees EC; Harvey RD; Han H; Ismail-Khan R; Minton S; Vahanian NN; Link C; Sullivan DM; Antonia S
Oncotarget; 2014 Sep; 5(18):8136-46. PubMed ID: 25327557
[TBL] [Abstract][Full Text] [Related]
2. Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer.
Campone M; Fumoleau P; Delecroix V; Deporte-Fety R; Perrocheau G; Vernillet L; Borg-Olivier O; Louboutin JP; Bissery MC; Riva A; Azli N
Ann Oncol; 2001 Jul; 12(7):909-18. PubMed ID: 11521794
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis.
Garcia AA; Iqbal S; Quinn D; Edwards S; Lenz HJ; Weber J
Invest New Drugs; 2006 Jan; 24(1):79-83. PubMed ID: 16379039
[TBL] [Abstract][Full Text] [Related]
4. Effect of Taxane Chemotherapy With or Without Indoximod in Metastatic Breast Cancer: A Randomized Clinical Trial.
Mariotti V; Han H; Ismail-Khan R; Tang SC; Dillon P; Montero AJ; Poklepovic A; Melin S; Ibrahim NK; Kennedy E; Vahanian N; Link C; Tennant L; Schuster S; Smith C; Danciu O; Gilman P; Soliman H
JAMA Oncol; 2021 Jan; 7(1):61-69. PubMed ID: 33151286
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma.
Kreis W; Budman DR; Fetten J; Gonzales AL; Barile B; Vinciguerra V
Ann Oncol; 1999 Jan; 10(1):33-8. PubMed ID: 10076719
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies.
Ramanathan RK; Ramalingam S; Egorin MJ; Belani CP; Potter DM; Fakih M; Jung LL; Strychor S; Jacobs SA; Friedland DM; Shin DM; Chatta GS; Tutchko S; Zamboni WC
Cancer Chemother Pharmacol; 2005 Apr; 55(4):354-360. PubMed ID: 15723261
[TBL] [Abstract][Full Text] [Related]
7. Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer.
Bleickardt E; Argiris A; Rich R; Blum K; McKeon A; Tara H; Zelterman D; Burtness B; Davies MJ; Murren JR
Cancer Biol Ther; 2002; 1(6):646-51. PubMed ID: 12642688
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
Massard C; Mateo J; Loriot Y; Pezaro C; Albiges L; Mehra N; Varga A; Bianchini D; Ryan CJ; Petrylak DP; Attard G; Shen L; Fizazi K; de Bono J
Ann Oncol; 2017 Jan; 28(1):90-95. PubMed ID: 28039155
[TBL] [Abstract][Full Text] [Related]
9. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.
Coleman RL; Duska LR; Ramirez PT; Heymach JV; Kamat AA; Modesitt SC; Schmeler KM; Iyer RB; Garcia ME; Miller DL; Jackson EF; Ng CS; Kundra V; Jaffe R; Sood AK
Lancet Oncol; 2011 Nov; 12(12):1109-17. PubMed ID: 21992853
[TBL] [Abstract][Full Text] [Related]
10. A phase I clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignancies.
Awada A; Zhang S; Gil T; de Valeriola D; Lalami Y; De Porre P; Piccart-Gebhart MJ
Curr Med Res Opin; 2007 May; 23(5):991-1003. PubMed ID: 17519066
[TBL] [Abstract][Full Text] [Related]
11. A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers.
Goel S; Desai K; Macapinlac M; Wadler S; Goldberg G; Fields A; Einstein M; Volterra F; Wong B; Martin R; Mani S
Invest New Drugs; 2006 Mar; 24(2):125-34. PubMed ID: 16683205
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of weekly docetaxel and daily temozolomide in patients with metastatic disease.
Tamaskar I; Mekhail T; Dreicer R; Olencki T; Roman S; Elson P; Bukowski RM
Invest New Drugs; 2008 Dec; 26(6):553-9. PubMed ID: 18626572
[TBL] [Abstract][Full Text] [Related]
13. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
Li JL; Zhang XR; Liu JW; Chen ZY; Lin YC; Wang YD; Chen Q; Nan KJ; Song SP; Han FC; Zhu YZ; Li LY; Zheng YH; Chu DT
Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):309-12. PubMed ID: 16875636
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours.
Awada A; Hendlisz A; Christensen O; Lathia CD; Bartholomeus S; Lebrun F; de Valeriola D; Brendel E; Radtke M; Delaunoit T; Piccart-Gebhart M; Gil T
Eur J Cancer; 2012 Mar; 48(4):465-74. PubMed ID: 22285181
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of indoximod in patients with advanced malignancies.
Soliman HH; Minton SE; Han HS; Ismail-Khan R; Neuger A; Khambati F; Noyes D; Lush R; Chiappori AA; Roberts JD; Link C; Vahanian NN; Mautino M; Streicher H; Sullivan DM; Antonia SJ
Oncotarget; 2016 Apr; 7(16):22928-38. PubMed ID: 27008709
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma.
Zakharia Y; McWilliams RR; Rixe O; Drabick J; Shaheen MF; Grossmann KF; Kolhe R; Pacholczyk R; Sadek R; Tennant LL; Smith CM; Kennedy EP; Link CJ; Vahanian NN; Yu J; Shen SS; Brincks EL; Rossi GR; Munn D; Milhem M
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34117113
[TBL] [Abstract][Full Text] [Related]
17. A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies.
Schwartz GH; Jones CB; Garrison M; Patnaik A; Takimoto C; McCreery H; Skinner M; Tolcher AW; Rowinsky EK
Invest New Drugs; 2004 Nov; 22(4):437-48. PubMed ID: 15292714
[TBL] [Abstract][Full Text] [Related]
18. A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors.
Van Den Neste E; de Valeriola D; Kerger J; Bleiberg H; Kusenda Z; Brassinne C; Bartholomeus S; Selleslags J; Hennebert P; Wythouck H; Cazenave I; Lefresne-Soulas F; Piccart M
Clin Cancer Res; 2000 Jan; 6(1):64-71. PubMed ID: 10656433
[TBL] [Abstract][Full Text] [Related]
19. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer.
Bayet-Robert M; Kwiatkowski F; Leheurteur M; Gachon F; Planchat E; Abrial C; Mouret-Reynier MA; Durando X; Barthomeuf C; Chollet P
Cancer Biol Ther; 2010 Jan; 9(1):8-14. PubMed ID: 19901561
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer.
Millward MJ; Zalcberg J; Bishop JF; Webster LK; Zimet A; Rischin D; Toner GC; Laird J; Cosolo W; Urch M; Bruno R; Loret C; James R; Blanc C
J Clin Oncol; 1997 Feb; 15(2):750-8. PubMed ID: 9053501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
